Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Tetrahydrobiopterin treatment in phenylketonuria: A repurposing approach.

Evers RAF, van Vliet D, van Spronsen FJ.

J Inherit Metab Dis. 2019 Aug 1. doi: 10.1002/jimd.12151. [Epub ahead of print] Review.

PMID:
31373030
2.

Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver Toxicity.

Li Y, Evers R, Hafey MJ, Cheon K, Duong H, Lynch D, LaFranco-Scheuch L, Pacchione S, Tamburino AM, Tanis KQ, Geddes K, Holder D, Zhang NR, Kang W, Gonzalez RJ, Galijatovic-Idrizbegovic A, Pearson KM, Lebron JA, Glaab WE, Sistare FD.

Toxicol Sci. 2019 Jul 1;170(1):180-198. doi: 10.1093/toxsci/kfz079.

PMID:
30903168
3.

Traumatic Experiences and the Midwifery Profession: A Cross-Sectional Study Among Dutch Midwives.

Kerkman T, Dijksman LM, Baas MAM, Evers R, van Pampus MG, Stramrood CAI.

J Midwifery Womens Health. 2019 Jul;64(4):435-442. doi: 10.1111/jmwh.12946. Epub 2019 Mar 19.

PMID:
30888739
4.

Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics.

Billington S, Salphati L, Hop CECA, Chu X, Evers R, Burdette D, Rowbottom C, Lai Y, Xiao G, Humphreys WG, Nguyen TB, Prasad B, Unadkat JD.

Clin Pharmacol Ther. 2019 Jul;106(1):228-237. doi: 10.1002/cpt.1373. Epub 2019 Mar 18.

PMID:
30673124
5.

Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects.

Zhao Y, Guo T, Fiksinski A, Breetvelt E, McDonald-McGinn DM, Crowley TB, Diacou A, Schneider M, Eliez S, Swillen A, Breckpot J, Vermeesch J, Chow EWC, Gothelf D, Duijff S, Evers R, van Amelsvoort TA, van den Bree M, Owen M, Niarchou M, Bearden CE, Ornstein C, Pontillo M, Buzzanca A, Vicari S, Armando M, Murphy KC, Murphy C, Garcia-Minaur S, Philip N, Campbell L, Morey-Cañellas J, Raventos J, Rosell J, Heine-Suner D, Shprintzen RJ, Gur RE, Zackai E, Emanuel BS, Wang T, Kates WR, Bassett AS, Vorstman JAS, Morrow BE; International 22q11.2 Brain and Behavior Consortium.

Am J Med Genet A. 2018 Oct;176(10):2172-2181. doi: 10.1002/ajmg.a.40359. Epub 2018 Oct 5.

PMID:
30289625
6.

Anthropomorphic measurements and nutritional biomarkers after 5 years of BH4 treatment in phenylketonuria patients.

Evers RAF, van Wegberg AMJ, van Dam E, de Vries MC, Janssen MCH, van Spronsen FJ.

Mol Genet Metab. 2018 Aug;124(4):238-242. doi: 10.1016/j.ymgme.2018.06.009. Epub 2018 Jun 20. No abstract available.

PMID:
30078395
7.

The application of low-altitude near-infrared aerial photography for detecting clandestine burials using a UAV and low-cost unmodified digital camera.

Evers R, Masters P.

Forensic Sci Int. 2018 Aug;289:408-418. doi: 10.1016/j.forsciint.2018.06.020. Epub 2018 Jun 26.

PMID:
30025566
8.

Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):900-915. doi: 10.1002/cpt.1115. Epub 2018 Jul 12.

PMID:
29756222
9.

Work-related adverse events leaving their mark: a cross-sectional study among Dutch gynecologists.

Baas MAM, Scheepstra KWF, Stramrood CAI, Evers R, Dijksman LM, van Pampus MG.

BMC Psychiatry. 2018 Mar 22;18(1):73. doi: 10.1186/s12888-018-1659-1.

10.

Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics.

Billington S, Ray AS, Salphati L, Xiao G, Chu X, Humphreys WG, Liao M, Lee CA, Mathias A, Hop CECA, Rowbottom C, Evers R, Lai Y, Kelly EJ, Prasad B, Unadkat JD.

Drug Metab Dispos. 2018 Feb;46(2):189-196. doi: 10.1124/dmd.117.077289. Epub 2017 Nov 14.

11.

Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome.

Bassett AS, Lowther C, Merico D, Costain G, Chow EWC, van Amelsvoort T, McDonald-McGinn D, Gur RE, Swillen A, Van den Bree M, Murphy K, Gothelf D, Bearden CE, Eliez S, Kates W, Philip N, Sashi V, Campbell L, Vorstman J, Cubells J, Repetto GM, Simon T, Boot E, Heung T, Evers R, Vingerhoets C, van Duin E, Zackai E, Vergaelen E, Devriendt K, Vermeesch JR, Owen M, Murphy C, Michaelovosky E, Kushan L, Schneider M, Fremont W, Busa T, Hooper S, McCabe K, Duijff S, Isaev K, Pellecchia G, Wei J, Gazzellone MJ, Scherer SW, Emanuel BS, Guo T, Morrow BE, Marshall CR; International 22q11.2DS Brain and Behavior Consortium.

Am J Psychiatry. 2017 Nov 1;174(11):1054-1063. doi: 10.1176/appi.ajp.2017.16121417. Epub 2017 Jul 28.

12.

Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.

Chu X, Chan GH, Evers R.

J Pharm Sci. 2017 Sep;106(9):2357-2367. doi: 10.1016/j.xphs.2017.04.007. Epub 2017 Apr 14. Review.

PMID:
28416420
13.

Dual-contrast agent photon-counting computed tomography of the heart: initial experience.

Symons R, Cork TE, Lakshmanan MN, Evers R, Davies-Venn C, Rice KA, Thomas ML, Liu CY, Kappler S, Ulzheimer S, Sandfort V, Bluemke DA, Pourmorteza A.

Int J Cardiovasc Imaging. 2017 Aug;33(8):1253-1261. doi: 10.1007/s10554-017-1104-4. Epub 2017 Mar 13.

PMID:
28289990
14.

Cardiac and Respiratory Motion Correction for Simultaneous Cardiac PET/MR.

Kolbitsch C, Ahlman MA, Davies-Venn C, Evers R, Hansen M, Peressutti D, Marsden P, Kellman P, Bluemke DA, Schaeffter T.

J Nucl Med. 2017 May;58(5):846-852. doi: 10.2967/jnumed.115.171728. Epub 2017 Feb 9.

15.

Antibiotic-Induced Elevations of Plasma Bile Acids in Rats Independent of Bsep Inhibition.

Li Y, Hafey MJ, Duong H, Evers R, Cheon K, Holder DJ, Galijatovic-Idrizbegovic A, Sistare FD, Glaab WE.

Toxicol Sci. 2017 May 1;157(1):30-40. doi: 10.1093/toxsci/kfx015.

PMID:
28108666
16.

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.

Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA.

Clin Pharmacol Ther. 2017 Apr;101(4):519-530. doi: 10.1002/cpt.525. Epub 2016 Dec 10.

PMID:
27943276
17.

Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.

Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L, Xiao G, Lee C, Lai Y, Liao M, Mathias A, Evers R, Humphreys W, Hop CE, Kumer SC, Unadkat JD.

Drug Metab Dispos. 2016 Nov;44(11):1752-1758. Epub 2016 Aug 19.

18.

Transporters affecting biochemical test results: Creatinine-drug interactions.

Chu X, Bleasby K, Chan GH, Nunes I, Evers R.

Clin Pharmacol Ther. 2016 Nov;100(5):437-440. doi: 10.1002/cpt.445. Epub 2016 Sep 15. Review.

PMID:
27509262
19.

Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.

Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, Chu X, Xiao G, Hop C, Evers R, Gan L, Unadkat JD.

Clin Pharmacol Ther. 2016 Oct;100(4):362-70. doi: 10.1002/cpt.409. Epub 2016 Aug 13.

20.

Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.

Brian W, Tremaine LM, Arefayene M, de Kanter R, Evers R, Guo Y, Kalabus J, Lin W, Loi CM, Xiao G.

Pharmacogenomics. 2016 Apr;17(6):615-31. doi: 10.2217/pgs.16.9. Epub 2016 Apr 5. Review.

PMID:
27045656
21.

The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?

Chu X, Bleasby K, Chan GH, Nunes I, Evers R.

Drug Metab Dispos. 2016 Sep;44(9):1498-509. doi: 10.1124/dmd.115.067694. Epub 2016 Jan 29. Review.

PMID:
26825641
22.

National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain.

Malayeri AA, Brooks KM, Bryant LH, Evers R, Kumar P, Reich DS, Bluemke DA.

J Am Coll Radiol. 2016 Mar;13(3):237-41. doi: 10.1016/j.jacr.2015.11.009. Epub 2016 Jan 23. Review. No abstract available.

23.

Evaluation of optimized breath-hold and free-breathing 3D ultrashort echo time contrast agent-free MRI of the human lung.

Gai ND, Malayeri A, Agarwal H, Evers R, Bluemke D.

J Magn Reson Imaging. 2016 May;43(5):1230-8. doi: 10.1002/jmri.25073. Epub 2015 Oct 13.

24.

Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.

Chu X, Shih SJ, Shaw R, Hentze H, Chan GH, Owens K, Wang S, Cai X, Newton D, Castro-Perez J, Salituro G, Palamanda J, Fernandis A, Ng CK, Liaw A, Savage MJ, Evers R.

Drug Metab Dispos. 2015 Jun;43(6):851-63. doi: 10.1124/dmd.115.063347. Epub 2015 Mar 26.

PMID:
25813937
25.

Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters.

Nguyen TV, Ukairo O, Khetani SR, McVay M, Kanchagar C, Seghezzi W, Ayanoglu G, Irrechukwu O, Evers R.

Drug Metab Dispos. 2015 May;43(5):774-85. doi: 10.1124/dmd.114.061317. Epub 2015 Mar 4.

PMID:
25739975
26.

Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics.

Wang L, Prasad B, Salphati L, Chu X, Gupta A, Hop CE, Evers R, Unadkat JD.

Drug Metab Dispos. 2015 Mar;43(3):367-74. doi: 10.1124/dmd.114.061580. Epub 2014 Dec 22.

PMID:
25534768
27.

Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship.

Kumar V, Prasad B, Patilea G, Gupta A, Salphati L, Evers R, Hop CE, Unadkat JD.

Drug Metab Dispos. 2015 Feb;43(2):284-8. doi: 10.1124/dmd.114.061614. Epub 2014 Dec 8.

PMID:
25488931
28.

Atypical presentation of GNE myopathy with asymmetric hand weakness.

de Dios JK, Shrader JA, Joe GO, McClean JC, Williams K, Evers R, Malicdan MC, Ciccone C, Mankodi A, Huizing M, McKew JC, Bluemke DA, Gahl WA, Carrillo-Carrasco N.

Neuromuscul Disord. 2014 Dec;24(12):1063-7. doi: 10.1016/j.nmd.2014.07.006. Epub 2014 Aug 7.

29.

A question-based approach to adopting pharmacogenetics to understand risk for clinical variability in pharmacokinetics in early drug development.

Evers R, Blanchard RL, Warner AW, Cutler D, Agrawal NG, Shaw PM.

Clin Pharmacol Ther. 2014 Sep;96(3):291-5. doi: 10.1038/clpt.2014.98.

PMID:
25141952
30.

[Reaction on 'Minocycline for schizophrenia: a brief overview'].

Evers R, van Amelsvoort T.

Tijdschr Psychiatr. 2014;56(8):561-2. Dutch. No abstract available.

31.

Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib.

Marcantonio EE, Ballard J, Gibson CR, Kassahun K, Palamanda J, Tang C, Evers R, Liu C, Zajic S, Mahon C, Mostoller K, Hreniuk D, Mehta A, Morris D, Wagner JA, Stoch SA.

J Clin Pharmacol. 2014 Nov;54(11):1280-9. doi: 10.1002/jcph.338. Epub 2014 Jun 25.

PMID:
24895078
32.

Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.

Salphati L, Chu X, Chen L, Prasad B, Dallas S, Evers R, Mamaril-Fishman D, Geier EG, Kehler J, Kunta J, Mezler M, Laplanche L, Pang J, Rode A, Soars MG, Unadkat JD, van Waterschoot RA, Yabut J, Schinkel AH, Scheer N.

Drug Metab Dispos. 2014 Aug;42(8):1301-13. doi: 10.1124/dmd.114.057976. Epub 2014 May 22.

PMID:
24855184
33.

Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.

Toubai T, Hou G, Mathewson N, Liu C, Wang Y, Oravecz-Wilson K, Cummings E, Rossi C, Evers R, Sun Y, Wu J, Choi SW, Fang D, Zheng P, Liu Y, Reddy P.

Blood. 2014 May 29;123(22):3512-23. doi: 10.1182/blood-2013-12-545335. Epub 2014 Apr 2.

34.

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, Chan G, Cai X, Valesky R, Fraser IP, Stoch SA.

Br J Clin Pharmacol. 2014 Sep;78(3):587-98. doi: 10.1111/bcp.12377.

35.

Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.

Prasad B, Evers R, Gupta A, Hop CE, Salphati L, Shukla S, Ambudkar SV, Unadkat JD.

Drug Metab Dispos. 2014 Jan;42(1):78-88. doi: 10.1124/dmd.113.053819. Epub 2013 Oct 11.

36.

Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.

Kenny JR, Liu MM, Chow AT, Earp JC, Evers R, Slatter JG, Wang DD, Zhang L, Zhou H.

AAPS J. 2013 Oct;15(4):933-40. doi: 10.1208/s12248-013-9495-1. Epub 2013 Jun 21.

37.

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.

Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L.

Drug Metab Dispos. 2013 Sep;41(9):1598-609. doi: 10.1124/dmd.113.052225. Epub 2013 Jun 21. Review.

PMID:
23792813
38.

In vitro methods to support transporter evaluation in drug discovery and development.

Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, Evers R; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):95-112. doi: 10.1038/clpt.2013.81. Epub 2013 Apr 10. Review. Erratum in: Clin Pharmacol Ther. 2013 Sep;94(3):412.

39.

Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation.

Toubai T, Sun Y, Luker G, Liu J, Luker KE, Tawara I, Evers R, Liu C, Mathewson N, Malter C, Nieves E, Choi S, Murphy KM, Reddy P.

Blood. 2013 May 16;121(20):4231-41. doi: 10.1182/blood-2012-05-432872. Epub 2013 Mar 21.

40.

PU.1-dependent transcriptional regulation of miR-142 contributes to its hematopoietic cell-specific expression and modulation of IL-6.

Sun Y, Sun J, Tomomi T, Nieves E, Mathewson N, Tamaki H, Evers R, Reddy P.

J Immunol. 2013 Apr 15;190(8):4005-13. doi: 10.4049/jimmunol.1202911. Epub 2013 Mar 15.

41.

In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.

Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM, Palamanda J, Evers R, Prueksaritanont T.

Drug Metab Dispos. 2013 Mar;41(3):668-81. doi: 10.1124/dmd.112.049668. Epub 2013 Jan 4.

PMID:
23293300
42.

Species differences in drug transporters and implications for translating preclinical findings to humans.

Chu X, Bleasby K, Evers R.

Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):237-52. doi: 10.1517/17425255.2013.741589. Epub 2012 Dec 21. Review.

PMID:
23256482
43.

Influence of donor microbiota on the severity of experimental graft-versus-host-disease.

Tawara I, Liu C, Tamaki H, Toubai T, Sun Y, Evers R, Nieves E, Mathewson N, Nunez G, Reddy P.

Biol Blood Marrow Transplant. 2013 Jan;19(1):164-8. doi: 10.1016/j.bbmt.2012.09.001. Epub 2012 Sep 13.

44.

Cardiovascular magnetic resonance characterization of peri-infarct zone remodeling following myocardial infarction.

Schuleri KH, Centola M, Evers KS, Zviman A, Evers R, Lima JA, Lardo AC.

J Cardiovasc Magn Reson. 2012 Apr 17;14:24. doi: 10.1186/1532-429X-14-24.

45.

Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers.

Melchior DL, Sharom FJ, Evers R, Wright GE, Chu JW, Wright SE, Chu X, Yabut J.

J Pharmacol Toxicol Methods. 2012 Mar;65(2):64-74. doi: 10.1016/j.vascn.2012.02.002. Epub 2012 Feb 26.

46.

Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease.

Tawara I, Sun Y, Liu C, Toubai T, Nieves E, Evers R, Alrubaie M, Mathewson N, Tamaki H, Reddy P.

J Leukoc Biol. 2012 Apr;91(4):667-75. doi: 10.1189/jlb.1011510. Epub 2012 Jan 18.

47.

Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.

Tawara I, Sun Y, Lewis EC, Toubai T, Evers R, Nieves E, Azam T, Dinarello CA, Reddy P.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):564-9. doi: 10.1073/pnas.1117665109. Epub 2011 Dec 27.

48.
49.

Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.

Toubai T, Tawara I, Sun Y, Liu C, Nieves E, Evers R, Friedman T, Korngold R, Reddy P.

Blood. 2012 Apr 19;119(16):3844-53. doi: 10.1182/blood-2011-10-384057. Epub 2011 Nov 18.

50.

Optimization of erythropoietin production with controlled glycosylation-PEGylated erythropoietin produced in glycoengineered Pichia pastoris.

Nett JH, Gomathinayagam S, Hamilton SR, Gong B, Davidson RC, Du M, Hopkins D, Mitchell T, Mallem MR, Nylen A, Shaikh SS, Sharkey N, Barnard GC, Copeland V, Liu L, Evers R, Li Y, Gray PM, Lingham RB, Visco D, Forrest G, DeMartino J, Linden T, Potgieter TI, Wildt S, Stadheim TA, d'Anjou M, Li H, Sethuraman N.

J Biotechnol. 2012 Jan;157(1):198-206. doi: 10.1016/j.jbiotec.2011.11.002. Epub 2011 Nov 9.

PMID:
22100268

Supplemental Content

Support Center